Abstract: The present invention relates to a novel compound and a composition for preventing or treating neuroinflammatory brain diseases, the composition comprising same as an active ingredient and, more specifically, to a pharmaceutical composition for preventing or treating neuroinflammatory brain diseases and a food composition for preventing or ameliorating neuroinflammatory brain diseases, the compositions comprising a compound represented by Chemical Formula 1 as an active ingredient. The novel compound of the present invention can be effectively used to provide a therapeutic agent for preventing or treating neuroinflammatory brain diseases, a food for ameliorating neuroinflammatory brain diseases, or a functional food for enhancing a cognitive function.

Abstract: The present invention relates to a novel xanthone compound, an optical isomer thereof or a pharmaceutically acceptable salt thereof that exhibits cytotoxicity against cancer cell lines and inhibits cancer cell growth, thereby exhibiting excellent preventive or therapeutic effects on various cancer cells.

Abstract: The present invention relates to new compounds derived from marine actinomycetes Streptomyces, and the new compound according to the present invention has an inhibitory effect of NO production on BV-2 microglia stimulated with LPS, and thus can be utilized for the prevention and treatment of neuroinflammatory diseases.

Abstract: Disclosed are a novel rhamnolipid compound, an optical isomer thereof, or a pharmaceutically acceptable salt thereof in the present disclosure. The novel rhamnolipid compound, the optical isomer thereof, or the pharmaceutically acceptable salt thereof selectively exhibits cytotoxicity to human cancer cell lines, thereby inhibiting the growth of cancer cells, and thus has particularly excellent preventive or therapeutic effects against the above-mentioned types of cancers.

Abstract: The present invention relates to new compounds derived from marine actinomycetes Streptomyces, and the new compound according to the present invention has an inhibitory effect of NO production on BV-2 microglia stimulated with LPS, and thus can be utilized for the prevention and treatment of neuroinflammatory diseases.

Abstract: Disclosed are a novel rhamnolipid compound, an optical isomer thereof, or a pharmaceutically acceptable salt thereof in the present disclosure. The novel rhamnolipid compound, the optical isomer thereof, or the pharmaceutically acceptable salt thereof selectively exhibits cytotoxicity to human cancer cell lines, thereby inhibiting the growth of cancer cells, and thus has particularly excellent preventive or therapeutic effects against the above-mentioned types of cancers.